Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC - ADR

NEW
NAS:ADAP (UK)   ADR
$ 0.55 -0.011 (-2.01%) 12:08 AM EST
At Loss
P/B:
1.75
Market Cap:
$ 139.87M
Enterprise V:
$ 28.27M
Volume:
1.68M
Avg Vol (2M):
1.07M
Warning! GuruFocus detected 5 Severe warning signs with ADAP. Try a 7-Day Free Trial to check it out.
Trade In:
Volume:
1.68M
Market Cap $:
139.87M
At Loss
Avg Vol (2M):
1.07M
Enterprise Value $:
28.27M
PB Ratio:
1.75
Website SEC Filings Stock PDF
Dataset
Financial Download GuruFocus Premium Icon Manual of Stocksâ„¢

Business Description

Adaptimmune Therapeutics PLC logo
Adaptimmune Therapeutics PLC
NAICS : 325412 SIC : 2834
ISIN : US00653A1079
https://www.adaptimmune.com
60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Share Class Description:

ADAP: ADR
Compare
Compare
PBYINKTXTILCSBRHURASTROMCRBACTUTSVTCKPTVRTXASX:CSLREGNXKRX:207940XBRU:ARGXXBRU:UCBALNYONCBNTXXKRX:068270
Traded in other countries / regions
ADAP.USA473A.Germany
IPO Date
2015-05-06
Description
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.

Financial Strength

4/10
Name Current Vs Industry Vs History
Cash-To-Debt 2.5
Equity-to-Asset 0.25
Debt-to-Equity 0.93
Debt-to-EBITDA -1.3
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.34
Distress
Grey
Safe
Beneish M-Score -1.14
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

5/10
Name Current Vs Industry Vs History
3-Year Revenue Growth Rate 120.5
3-Year EBITDA Growth Rate 10.3
3-Year EPS without NRI Growth Rate 11.6
3-Year FCF Growth Rate -22.2
3-Year Book Growth Rate -57.1

Momentum Rank

4/10
Name Current Vs Industry Vs History
5-Day RSI 35.15
9-Day RSI 38.77
14-Day RSI 41.11
3-1 Month Momentum % -18.14
6-1 Month Momentum % -53.54
12-1 Month Momentum % -62.42

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.85
Quick Ratio 3.82
Cash Ratio 2.93
Days Sales Outstanding 10.36

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -13.6
Shareholder Yield % -33.89

Profitability Rank

3/10
Name Current Vs Industry Vs History
Operating Margin % -25.76
Net Margin % -25.43
FCF Margin % -32.02
ROE % -67.8
ROA % -15.08
ROIC % -39.29
3-Year ROIIC % -11.71
ROC (Joel Greenblatt) % -99.87
ROCE % -30.65

GF Value Rank

2/10
Name Current Vs Industry Vs History
PS Ratio 0.81
PB Ratio 1.75
Price-to-Tangible-Book 1.82
EV-to-EBIT -0.41
EV-to-EBITDA -0.49
EV-to-Revenue 0.16
EV-to-Forward-Revenue 0.58
EV-to-FCF -0.5
Price-to-GF-Value 0.08
Price-to-Net-Current-Asset-Value 18.22
Earnings Yield (Greenblatt) % -243.9
FCF Yield % -40.08

Financials (Next Earnings Date:2025-03-06 Est.)

ADAP's 30-Y Financials
AAPL
Income Statement Breakdown FY
Not Enough Data
AAPL
Balance Sheet Breakdown
Not Enough Data
AAPL
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:ADAP

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Adaptimmune Therapeutics PLC Executives

Details

GF Value: $6.45

ADAP

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 175.041
EPS (TTM) ($) -0.18
Beta 2.37
3-Year Sharpe Ratio -0.16
3-Year Sortino Ratio -0.25
Volatility % 62.37
14-Day RSI 41.11
14-Day ATR ($) 0.043608
20-Day SMA ($) 0.582315
12-1 Month Momentum % -62.42
52-Week Range ($) 0.51 - 2.05
Shares Outstanding (Mil) 255.88

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Adaptimmune Therapeutics PLC Filings

Filing Date Document Date Form
No Filing Data

Adaptimmune Therapeutics PLC Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Adaptimmune Therapeutics PLC Frequently Asked Questions

What is Adaptimmune Therapeutics PLC(ADAP)'s stock price today?
The current price of ADAP is $0.55. The 52 week high of ADAP is $2.05 and 52 week low is $0.51.
When is next earnings date of Adaptimmune Therapeutics PLC(ADAP)?
The next earnings date of Adaptimmune Therapeutics PLC(ADAP) is 2025-03-06 Est..
Does Adaptimmune Therapeutics PLC(ADAP) pay dividends? If so, how much?
Adaptimmune Therapeutics PLC(ADAP) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.